Introduction
Patients with coronary artery disease on aspirin and P2Y12 inhibitors are at risk of both bleeding and ischaemic events. 1, 2 Many studies demonstrated that on-treatment P2Y12-receptor platelet reactivity is a prognostic marker for both adverse events; low on-treatment platelet reactivity is associated with an increased risk of bleeding, whereas high on-treatment platelet reactivity is linked to an increased risk of ischaemia. 3, [4] [5] [6] Whether tailoring of therapy based on low platelet reactivity can prevent bleeding has yet to be established. Though, patients with a high a-prior risk of ischaemia and high platelet reactivity seem to benefit from tailoring of therapy. 7 Therefore, current cardiology guidelines state that 'platelet function tests (PFTs) may be used in specific high-risk situations' to aid in the therapy decision-making process (class IIb level C), 8, 9 although no advise on type of PFT, cut-off values or time point of measurement is given. As a vast amount of studies regarding the predictive value of several PFTs and influencing factors are available, [10] [11] [12] [13] [14] [15] [16] it is challenging for a
The consensus document does not recommend one test over another, and the degree of interchangeability of these PFTs with proposed therapeutic windows is currently unknown. In addition, as clinical and laboratory variables differently influence platelet reactivity measured by individual PFTs, 18 it is likely that these factors also affect the PFT classification of patients in low, optimal, or high platelet reactivity categories. Therefore, we explored (i) the level of agreement between the VerifyNow, Multiplate, and LTA using the therapeutic windows as proposed by the consensus documents; and (ii) the influence of co-medication, patient characteristics, and laboratory parameters on this level of agreement, in a clinical explorative study including high-risk patients with coronary artery disease on P2Y12 inhibitors.
Methods Study population and design
In this explorative clinical study, on-treatment platelet reactivity was measured in high-risk patients on clopidogrel, prasugrel, or ticagrelor, after treatment with elective or emergency percutaneous intervention (PCI) in the Maastricht University Medical Centreþ (MUMCþ). Patients included in this analysis underwent PCI from April 2014 until October 2015. Cardiologists referred vulnerable patients to the outpatient department of vascular medicine to assess bleeding and ischaemic risk during treatment with P2Y12 inhibitors. During the visit, compliance, comorbidities, co-medication, and previous medical history were recorded. Three to eight hours after last drug intake blood was drawn for the PFTs, complete blood count, and renal function. Inclusion criteria were the use of a P2Y12 inhibitor and PCI in the preceding 6 months (>7 days after PCI). High-risk or vulnerable patients were defined as having !2 of the following risk factors for bleeding and/ or ischaemic events: old age (!75 years), female gender, renal dysfunction [estimated Glomerular Filtration Ratio (eGFR) <60 mL/min] or anaemia at time of PCI (haemoglobin level <13.2 g/dL for men, <11.8 g/ dL for women), low body weight (<60 kg), hypertension (as previously diagnosed), diabetes mellitus, previous stroke, use of non-steroidal antiinflammatory drugs or selective serotonin reuptake inhibitors, triple antihaemostatic therapy, previous in-stent thrombosis, and high-risk stenting (multivessel PCI or main coronary artery stenting). 5, 19 Patients were excluded in case of platelet count <100 000/mL, signs of active infection at scheduled PFT measurement, a new ischaemic event or PCI within 7 days before the scheduled measurement, and non-compliance. The latter was checked during the visit by interview and by contacting the pharmacy to confirm dispensing of the drugs. Oral anticoagulant users were not excluded, as P2Y12 inhibitor response monitoring could have particular value in real-world patients using both P2Y12 inhibitors and oral anticoagulants, in which the balancing between bleeding and thrombotic risk is even more precarious. 20 The medical ethical committee of the MUMCþ approved this study as an evaluation of patient care analysis, as the visit to the outpatient department and all blood tests were conducted solely for patient care. According to the MUMCþ protocol regarding anonymous data handling, the opt-out approach was used; patients could opt-out of anonymous data handling for this analysis. Those patients who decided to opt-out were excluded from this study.
Blood collection and preparation of platelets and plasma
Patients were asked to avoid fat containing food for 4 h before blood withdrawal. Venous blood was collected by venipuncture of the antecubital vein using 21 gauge needles and vacuum tubes. The tourniquet pressure was released during the filling of the first blood tube, which was not used for the PFTs to avoid undesired platelet activation. Blood for all PFTs was drawn simultaneously and all measurements were started within 1 h after blood collection.
For the preparation of platelet-rich plasma, citrated-blood was centrifuged at 170 g for 10 min at 18 C. Platelet poor plasma was obtained by centrifugation of citrated blood at 2500 g for 5 min and then at 10 000 g for 10 min at 18 C.
Platelet function tests and therapeutic windows VerifyNow
Blood was collected in 3.2% sodium citrate Vacuette partial-fill tubes (2 mL; Greiner Bio-One, GmbH, Kremsmünster, Austria). For the VerifyNow P2Y12 assay (Accumetrics Inc, San Diego, CA, USA), samples were run according to the package insert. Results were expressed in P2Y12 reaction units (PRU) in response to ADP-prostaglandin E1. We defined the therapeutic window as 85-208 PRU, with low ontreatment platelet reactivity defined as PRU <85 and high on-treatment platelet reactivity as PRU >208, according to Tantry et al. 
Multiplate
Blood was collected in Hirudin Blood Tubes (3 mL, Double Wall; Verum Diagnostica GmbH, Munich). ADP (6.4 mmol/L)-induced platelet aggregation was measured by the Multiplate Analyser (Dynabyte, Munich, Germany), according to instructions from the manufacturer. Results were expressed as arbitrary aggregation units (AU).
We defined the therapeutic window as 19-46 AU, with low ontreatment platelet reactivity defined as AU <19 and high on-treatment platelet reactivity as AU >46, according to Tantry et al. 3 
Light transmission aggregometry
Blood was collected in 3.2% sodium citrate Vacuette tubes (9 mL; Greiner Bio-One). Platelet count in platelet rich plasma was adjusted with autologous platelet poor plasma to 250 Â 10 9 platelets/L. In vitro platelet aggregation was measured in response to ADP (20 lmol/L, Chrono-Par, CH 384) at 37 C (Chrono-log 490-4D; Chrono-Log Corp.). The main result was the percentage of maximal platelet aggregation. Reasons for sample exclusion were haemolysis, platelet count <100 000/mL, and an unstable baseline.
We defined the therapeutic window as 20-59%, with low ontreatment platelet reactivity defined as maximal aggregation <20%, according to Kerneis et al. 21 and high on-treatment platelet reactivity as maximal aggregation >59%, according to Bonello et al.
17

Study endpoints
The main endpoints of this analysis were (i) the agreement between PFT pairs-VerifyNow-Multiplate, VerifyNow-LTA, Multiplate-LTA-when classifying patients as having high, optimal, and low on-treatment platelet reactivity according to the therapeutic windows; and (ii) the influence of co-medication, patient characteristics, and laboratory parameters on the performance of individual PFTs and the level of agreement between PFTs.
Statistical analysis
Continuous variables are expressed as either mean 6 standard deviation for normally distributed traits or median 6 inter-quartile range otherwise; categorical variables are expressed as counts and percentages. Continuous variables were compared using Student's t-test for normally distributed traits; otherwise the Mann-Whitney U test was used. Categorical variables were compared using the v 2 test or
Fisher's exact test when frequencies were <5. Agreement between assays regarding therapeutic windows was assessed with quadratic weighted Kappa (j) statistics. Kappa indicates the proportion of agreement between rankings made by two or more tests in relation to two or more categories, beyond that expected by chance. Values of 0 were considered poor agreement, 0.01-0.20 slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 substantial, and 0.81-1 almost perfect agreement. 22 Simple correlation between PFTs was assessed with Pearson correlation coefficients (q). Univariate linear regression was performed to identify covariates that influence the magnitude of platelet reactivity per test. Test results were standardized using inverse normal transformation. The standardized values were plotted for the different test-pairs and residuals were calculated reflecting the discrepancy between testpair results. To identify determinants of discrepancies between test results, we performed linear regression of covariates on test-pair residuals.
Statistical analyses were performed with IBM SPSS statistics version 21.0 and R statistics (R Version 3.2.2, https://www.r-project.org). j statistics were performed using 'Clinical Research Calculators' from vassarstats.net. Statistical significance was assumed at P-value <0.05.
Results
Study population
Our study population consisted of 145 patients. Most prevalent risk factors were old age (50%), diabetes mellitus (40%), hypertension (79%), anaemia, and renal dysfunction at time of PCI (37% and 61%, respectively) ( Table 1) . Antithrombotic therapy with a combination of clopidogrel and aspirin was most frequently used (59%), followed by clopidogrel with oral anticoagulants (18%) and prasugrel with aspirin (14%) (Figure 1) .
Agreement between platelet function tests
Simple correlation between platelet reactivity values was q ¼ 0.55 (P < 0.001) for the VerifyNow-Multiplate, q ¼ 0.67 (P < 0.001) for the VerifyNow-LTA, and q ¼ 0.49 (P < 0.001) for the Multiplate-LTA.
Classifying 145 patients in low, optimal, and high on-treatment platelet reactivity according to the three tests resulted in classification in the same category in 37 (25.5%) patients, whereas 102 (70.3%) patients were classified in two categories and six (4.1%) patients in Table 2 .
For all platelet function test-to-test comparisons, the agreement between the platelet reactivity classifications was slight to moderate. When comparing VerifyNow with Multiplate, 72 patients (50%) were classified in different platelet reactivity categories, j ¼ 0.41 [95% confidence interval (CI) 0.28-0.53]. Overall, patients were ranked more often in higher platelet reactivity categories by Multiplate (Figure 2A) .
VerifyNow and LTA classified 69 patients (48%) in different categories, j ¼ 0.36 (95% CI 0.24-0.49). In most cases of disagreement, the LTA ranked patients in the optimal platelet reactivity category whereas the VerifyNow measured either low or high platelet reactivity ( Figure 2B ). Multiplate and LTA classified 81 patients (56%) in different categories, j ¼ 0.20 (CI not calculable), of which two patients were classified as having low platelet reactivity by the LTA and high platelet reactivity by the Multiplate. Again, the Multiplate ranked patients more often in higher platelet reactivity categories ( Figure 2C) .
Similar results were obtained for the subgroup of patients on clopidogrel regarding correlation and agreement between PFTs (n ¼ 116) (see Supplementary material online, Tables S1 and S2).
Influence of covariates on test-to-test platelet reactivity comparisons
To identify covariates that influence the PFTs to a different degree and thereby also affect the level of agreement between the PFTs, we first determined whether covariates would cause one PFT to measure a different degree of platelet inhibition than the other PFT. (For the influence of covariates on individual PFTs see Supplementary material online, Table S3 .) Therefore, linear regression of covariates and test-to-test residuals of the standardized platelet reactivity results was performed (see Supplementary material online, Table  S4A ). PFT results were standardized in order to enable comparison of the PFTs with their different units and scales of measurement. If a covariate significantly influences test-to-test residuals, this means that this particular covariate has a significantly larger or opposite effect on one PFT compared with the other. The VerifyNow measured significantly higher residual platelet reactivity than the Multiplate with increasing age, whereas the VerifyNow measured lower platelet reactivity with increasing haemoglobin level, platelet count, prasugrel or ticagrelor use, and vitamin K antagonist use (see Supplementary material online, Table S4A ).
When comparing VerifyNow-LTA measurements, the VerifyNow measured significantly higher platelet reactivity than the LTA with increasing age, diabetes mellitus, and esomeprazole use. With increasing haemoglobin level, eGFR, and in case of ticagrelor or vitamin K antagonist use, VerifyNow measured significantly lower platelet reactivity than the LTA.
From the LTA-Multiplate comparison, the LTA measured significantly higher platelet reactivity than the Multiplate in case of previous stroke, use of calcium channel blockers, and with increasing haemoglobin level. The LTA measured significantly lower platelet reactivity in case of prasugrel, ticagrelor, and aspirin use and with decreasing platelet count and fibrinogen level.
In the subgroup of clopidogrel users, similar results were obtained regarding the influence of covariates on the PFT comparisons (see Supplementary material online, Table S4B ).
Influence of covariates on agreement between therapeutic windows
Finally, the influence of covariates on the agreement between the tests with respect to classification of patients in low, optimal, and high on-treatment platelet reactivity was investigated (see Supplementary material online, Table S5A ). The VerifyNow and Multiplate agreed significantly more often in patients with previous stroke (P ¼ 0.044) or treated with proton pump inhibitors (P ¼ 0.032). A lower level of agreement was observed in patients on prasugrel compared with clopidogrel users (P ¼ 0.005), which is in concordance with the finding that prasugrel use resulted in lower platelet reactivity measured by the VerifyNow than by the Multiplate.
When comparing the categorization of patients in platelet reactivity groups using VerifyNow and LTA, there was significantly more disagreement in patients with previous stroke (P ¼ 0.016) or a lower haemoglobin level (P ¼ 0.003). Again, this corresponds to the finding that with lower haemoglobin levels the VerifyNow measured relatively higher platelet reactivity than the LTA.
Agreement between the LTA and Multiplate was significantly lower in case of increasing age (P ¼ 0.013), aspirin use (P ¼ 0.029), ticagrelor use (P ¼ 0.035), lower haemoglobin level (P ¼ 0.003), and higher platelet count (P ¼ 0.045). This is in line with the fact that all these variables (except age) influenced platelet reactivity measured by these tests differently; the Multiplate measured relatively higher platelet reactivity than the LTA.
Again, in the subgroup of clopidogrel users similar covariates influenced the level of PFT agreement (see Supplementary material online, Table S5B ).
Discussion
Patients on dual antiplatelet therapy after PCI are at risk of lifethreatening bleeding and (recurrent) ischaemic events.
1,2 The magnitude of this problem is illustrated by the vast amount of studies reporting on platelet reactivity as a biomarker for identification of high-risk patients. Currently, there is no PFT that is universally regarded as the gold standard for the assessment of antiplatelet therapy. Tantry et al. 3 made an important step forward by proposing therapeutic windows based on the most relevant and reliable evidence. The results of our clinical explorative study suggest that the quest for optimal therapeutic windows has not come to an end. There was only slight to moderate agreement between the VerifyNow, Multiplate, and LTA when classifying patients in low, optimal, and high on-treatment platelet reactivity as proposed by Tantry et al. 3 Studies carried out prior to this consensus document reported similar results regarding the classification of patients in optimal and high platelet reactivity categories, 11,23-27 but we further explored the agreement between PFTs by including a low platelet reactivity category, patients on prasugrel or ticagrelor and patients on oral anticoagulants, as these patients have a particularly high risk of bleeding. 20 In addition, we identified several covariates that influenced the level of agreement between the tests. An explanation for the low level of agreement between the tests in our study might be the fact that the therapeutic windows from the consensus documents 3, 17 were based on several different studies. 10, 12, 13, 15, 21 There was a large methodological variation between these studies regarding the indication for PCI, time between PCI and platelet reactivity measurement, patient population, and type of P2Y12 inhibitor. Previous studies showed that the timing of platelet reactivity measurement is important as platelet reactivity tends to be higher in the acute phase of acute coronary syndrome and post PCI than at later time points. 10, 28 Our results support the idea that differences in patient populations and type of P2Y12 inhibitor also contribute to the low level of agreement between the PFTs. Specifically, we found that drug use (prasugrel, ticagrelor, aspirin), laboratory parameters (e.g. haemoglobin level), and patient characteristics directly ). For example, the VerifyNow measured significantly lower platelet reactivity than the Multiplate in patients on prasugrel and ticagrelor, possibly because the VerifyNow includes prostaglandin E1 to suppress P2Y1-induced platelet activation, making the assay more sensitive to stronger P2Y12 inhibition. 29 Likewise, lower haemoglobin levels reduced the agreement between both VerifyNow-LTA and Multiplate-LTA. In concordance with previous studies, we found that with decreasing haemoglobin levels both the VerifyNow and Multiplate measured relatively higher platelet reactivity. 18, 30, 31 A possible explanation is that a low number of red blood cells increases the light transmission 31 and prevents impediment of aggregate formation by particle crowding. 30 Remarkably, we found that aspirin decreases agreement between the Multiplate and LTA, whereas the therapeutic windows were based on patients using aspirin. Aspirin had a more pronounced platelet reactivity lowering effect on the LTA, possibly because thromboxane production is important for the amplification of the aggregation response in the LTA, 32 whereas the Multiplate was proved insensitive to aspirin. 33 All together, these findings suggest that the level of agreement between PFTs regarding categorization of vulnerable patients into platelet reactivity categories, based on the proposed therapeutic windows, might be determined by (i) similarity in the indication(s) for PCI and time between the intervention and platelet reactivity measurement; (ii) specific patient-related factors that have different effects on the various PFTs; and (iii) the type of P2Y12 inhibitor.
Partly due to the nature of this study, in which real-world patients in a clinical setting were included, this study has some limitations. Our patient population is heterogeneous regarding time between PCI and point of measurement (although always >7 days after intervention), timing of platelet reactivity measurement after the intake of last P2Y12 inhibitor dose (3-8 h), indication for PCI, co-morbidities, and use of co-medication. Furthermore, the sample size was small, leaving the study underpowered for factors with smaller effects on agreement. Likewise, we could only include a few patients on prasugrel or ticagrelor. Finally, it would have been particularly interesting to see which PFT with associated therapeutic window is the best predictor of clinical outcomes in a vulnerable patient population. However, our study was not powered to answer this question, nor was it the primary aim of this analysis.
Our results indicate that the PFTs, with accompanying therapeutic windows, are not interchangeable. Hence, the type of PFT, when used to tailor therapy, can directly affect the treatment strategy. This may be even more relevant for patients who have multiple factors that influence the individual tests and/or the test agreement. For the therapeutic windows to monitor P2Y12-receptor platelet inhibition to become an established concept for vulnerable patients, we suggest that future studies with larger sample sizes simultaneously relate several PFTs to clinical endpoints in a vulnerable patient population. Optimally, specific windows should be constructed for different situations, in which patient characteristics, type of P2Y12-inhibitor, and laboratory parameters are taken into account.
Conclusion
In this clinical explorative study, the agreement between the VerifyNow, Multiplate, and LTA when used to classify real-world vulnerable patients as having high, optimal, and low on-treatment platelet reactivity according to the proposed therapeutic windows from the consensus paper was slight to moderate. In addition, this level of agreement between the tests was significantly influenced by patient characteristics, type of P2Y12 inhibitor, and laboratory parameters.
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